"We're witnessing an increasing role for radiopharmaceuticals as a pillar of cancer treatment given their meaningful clinical activity and high tolerability compared to chemotherapy," said Dr. Reinier Hernandez, Assistant Professor of Medical Physics and Radiology at the University of Wisconsin-Madison, and principal investigator of the studies. "This is very exciting for the future of cancer treatment, and we have just begun to scratch the surface. We look forward to continuing to leverage radiopharmaceuticals, through our collaboration with WARF Therapeutics and SHINE, to enable new avenues to treat the most aggressive types of cancer."
"These close relationships between industry and academia are the heart and soul of WARF Therapeutics," said Jon Young, Head of WARF Therapeutics. "This partnership demonstrates how productively and efficiently we can move from concept to prototype, from bench to bedside, and get drugs in the hands of clinicians to improve patient outcomes."
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Hernandez's lab chose SHINE as its partner for sourcing Lu-177 given Ilumira's superior quality and US-based production. This ensures faster, flexible delivery, lower costs, and the ability to scale. It also enables research and clinical trials to stay on schedule, and for patients to benefit sooner, as this US supply helps bring innovative cancer therapies to market faster. SHINE has the highest production capacity in the U.S for Lu-177, enabling production of hundreds of thousands of cancer-fighting doses annually.
"This is further validation that Ilumira is more effective than the standard of care for cancer treatment," said Greg Piefer, CEO and founder of SHINE. "We're on the verge of an amazing frontier in cancer treatment. I believe we're going to move from merely fighting disease progression to actually curing patients. We're thrilled to support the University of Wisconsin in its groundbreaking work and excited to play even a small role in world-changing programs like these. We look forward to our continued collaboration to create a brighter future for patients."
The group plans to have WT-7695 and ART-101 move on to human trials within the next year. WARF, the proprietor of both technologies, is seeking partners for continued development and commercialization to advance these promising radiopharmaceuticals. Dr. Hernandez's team will give presentations on these and other findings at the 2024 Annual Congress of the European Association of Nuclear Medicine (EANM).
